Mr. Peter Bains is the Director of Syngene, since 2011.
Peter has more than two decades of experience in the global pharmaceutical space. With strategic and operational leadership expertise across geographies, functions and business segments, he brings a global perspective with a forte in emerging markets, particularly China and India.
Peter has implemented strategic goals and objectives for Syngene and enables the Board of Directors to fulfil its governance function. In addition, he also directs and leads us towards the achievement of Syngene's philosophy, mission and strategy.
Before his appointment to the Board of Syngene in 2010, Peter had a 23-year career at GlaxoSmithKline, where he held several roles including Head of Global Marketing and Senior VP of Commercial Development (International). During his tenure, he helped establish several GSK brands as brand leaders and conceived, developed and implemented an organizational redesign in GSK's International Region.
From 2009, he has been a consultant specialising in supporting strategic growth opportunities in small- and medium-sized innovation-based life science companies.
Peter completed his B.Sc Combined Honours in Physiology/ Zoology from Sheffield University. During his spare time, he enjoys spending time with his family and is a keen sports enthusiast.
Dr. Manoj Nerurkar is the Chief Operating Officer of Syngene since April 2012. He joined Syngene in 2009 to head the Formulation Development Center, and was the Vice President & Head - Small Molecule Discovery & Development till March 2012.
As the head of the senior leadership team of scientific department, business development and project management, Manoj has been instrumental in terms of both strategic leadership and operational management in underpinning Syngene's recent growth and evolution. He is also responsible for implementing the strategies for growth and enabling operational excellence across Syngene.
He identifies and builds new business opportunities to maintain the company's market leadership position and profitability. He is working with the Syngene Board of Directors to bring future opportunities to fruition through adequate investment in new infrastructure and technologies.
Manoj has extensive experience in the development of oral solid & injectable dosage forms from Phase I to commercialization. Prior to joining Syngene, Manoj worked for Novartis and was responsible for setting up their Drug Development R&D center in India.
Manoj has also worked with Bristol-Myers Squibb in New Jersey, for 10 years, where he had the opportunity to work on the development of various dosage forms including immediate and modified release tablets, capsules, and conventional and depot injectable formulations of small and biological molecules. He has two commercial products to his credit which include an intravenous formulation of BMS' first biologic molecule - Orencia and an intramuscular formulation of an anti-schizophrenic drug - Abilify.
Manoj obtained his PhD in Pharmaceutical Chemistry from University of Kansas, and has completed a Management Program from the Wharton School of Business. He holds several patents in the Formulation Development area and has several publications to his credit in international peer-reviewed journals.
Mr. Chinappa is the President - Finance, Syngene as of April 2008. Prior to this, he was the Vice President - Finance, Biocon Limited since 2004.
He joined the company as Senior Manager - Finance in 1999 and has over 20+ years of experience.
Chinappa oversees all the finance and fiscal management of company operations, and is responsible for the overall management and direction of the company. He provides leadership and coordination in the administrative, business planning, accounting and budgeting efforts of the company. As a member of the senior leadership team, he also plays an important role on all strategic and tactical matters as they relate to budget management, cost benefit analysis, forecasting needs and the securing of new funding.
He has been instrumental in setting up various EOU's and an SEZ. His astute guidance has resulted in the successful acquisition of IP from Nobex, investment and other strategic collaborations with various biotech companies. He has also been an integral part of the team that has engineered the strategic partnership between Syngene and BMS, and other such initiatives to position Biocon as a leading biotech player manufacturing affordable bio-pharmaceuticals.
Mr. Chinappa completed his graduation in Commerce from St. Joseph's College of Commerce, Bangalore in 1989 and Chartered Accountancy from the Institute of Chartered Accountants, India in 1992. Prior to joining Biocon, Chinappa worked with ITC Limited and did his Chartered Accountancy Training with M/s Price WaterhouseCoopers.
Dr. Anita Chugh is the Head – Biology and has joined Syngene in 2011, and is responsible for providing the scientific leadership to the different programs at Syngene.
Anita is responsible for the overall management of the Biology function. She has worked operationally for 15 years in discovery biology, spanning both empirical and contract service roles.
She has extensive experience in the area of urology, metabolics and inflammation, and has a track record of identification and progression of candidates to clinics.
Prior to joining Syngene, Anita was associated with Aurigene Discovery Technologies Ltd as Research Director in Discovery Biology and Advinus Therapeutics Pvt Ltd as Senior Director and Head, Biology. She provided leadership to Discovery Biology including screening, molecular-cell biology and in- vivo. Her key responsibilities included scientific guidance, motivating and leading team for preparing and achieving significant success in internal and collaborative research programs, practices, building culture for innovation.
Anita gained her M.Sc. and Ph.D. from the All India Institute of Medical Sciences, and her Post Doctoral Fellowship from McMaster's University in Ontario, Canada, before returning to India in 1995.
She has several published patents and publications to her credit.
Dr. K. S. Rao (B.V.Sc & A.H., M.V.Sc., Ph.D.,) is a Board Certified Toxicologist with more than 35 years of global experience in safety evaluation - toxicology supporting drug discovery & development, agrochemical research and development and is associated with Syngene since May 2011.
He is Emeritus Member of the Society of Toxicology – SOT in US. He is the first Indian Toxicologist to be appointed for this status for being a member of the SOT for 40 years.
Dr. Rao has led multidisciplinary teams in designing/constructing, maintaining, managing of preclinical research – toxicology & animal breeding/stock facilities (to international standards-guidelines, fulfilling Good Laboratory Practice (GLP) requirements) in USA and India.
Dr. Rao has published papers and presented papers in international seminars. He is a member and actively contributed in international organizations in the field of toxicology. He is the principal author of more than 200 safety evaluation study reports of various new compounds marketed or to be marketed. These reports are submitted to various regulatory authorities of several countries, including, FDA & EPA (U.S.A), European, Japanese Health and Indian Regulatory Authorities.
Dr. Dhananjay Patankar joined Syngene in Oct 2010 and currently heads formulation, biologics development and cGMP manufacturing for all biologics (recombinant proteins, antibodies and other macromolecules) as well as drug products (variety of dosage forms for small and large molecules).
In addition, he serves as the Chairman of the Institutional Animal Ethics Committee.
Dhananjay is a Chemical Engineer with 17 years of industry experience in product development, manufacturing and commercialization of recombinant biotherapeutics for Indian and global markets. In his career, Dhananjay has led the development and manufacturing of 7 recombinant biopharmaceuticals that are currently sold in the Indian and other markets.
He has established manufacturing facilities, managed commercial manufacturing operations, and successfully obtained EU-GMP certification for a biologic drug substance and drug product facility. Immediately prior to joining Syngene, Dhananjay led the CMC development of a biosimilar which has recieved Marketing Authorization in Europe, wherein he directly supervised areas such as process characterization and validation, analytical development and validation, product characterization and comparability, and CMC regulatory strategy.
Dhananjay currently serves as Chair of a US Pharmacopeia Expert Committee for Biologics and Member of US Pharmacopeia Council of Experts. He previously served as an industry representative on a National Task Force for establishing regulatory pathway for biosimilars in India.
Prior to joining Syngene, Dhananjay was associated with Intas Biopharmaceuticals Ltd. Ahmedabad, as Chief Operating Officer. He was also associated with the Biotechnology Division of Wockhardt Research Center, Aurangabad as a Sr. Scientist and Group Head for product development and manufacturing.
Dhananjay did his Postdoctoral Fellowship at the Dept. of Chemical and Biochemical Engineering, Rutgers University, Piscataway, NJ (USA). He obtained his Ph.D. (1992) and M.S. (1989) in Chemical Engineering from University of Utah, Salt Lake City and B.Tech. in Chemical Engineering from Indian Institute of Technology, Bombay, 1986.
Dr. Joachim Demnitz joined Syngene in August, 2013. Prior to that he spent 11 years at Neurosearch (Denmark)and its spinout drug discovery company Aniona, of which Joachim is also a co-founder.
At both companies he occupied multiple roles, being Head of Medicinal Chemistry and Director for External Chemistry, a capacity in which he was in charge of several outsourced programs at CROs in Europe and Asia, including a 9 year collaboration with Syngene. In a simultaneous role as Project Manager, Joachim ran several early programs for the discovery and development of novel ion channel modulators, notably the first herg channel opener (NS1643), ASIC channel blockers (Pain) as well as the design, optimization and promotion into development of novel IK channel blockers for inflammation (IBD).
Joachim is a German national and obtained his BSc in Chemistry from Imperial College (London), PhD in Organic Synthesis from the University of Cambridge (under Prof. R. A. Raphael) and “post-docked” with Professor J. D. White (Oregon State University) working on intra-molecular Diels Alder reactions applied to the chiral synthesis of the tetracycline pillaromycinone. In the 80s and 90s he spent 6 years at Sandoz (Basel) in preclinical chemistry and over 10 years at the Universities of Brasília (UnB) and Recife (UFPe) in Brazil both as an academic member of staff as well as an external development expert within German Government-sponsored Projects. Joachim has co-authored more than 40 articles and patents.
Dr. Jegadeesh Thampi joined Syngene in 2005 and currently heads the Chemical Development with the overall responsibility of the development and manufacturing of small molecules (Process Chemistry, Process Engineering, Process Analytical, Technology Transfer, Scale-up and cGMP Manufacturing) and Polymer Science.
As the head of the Chemical Development Division, Jegadeesh has been instrumental in building functional and leadership capabilities including early stage route scouting to late stage development capabilities
He identifies and builds niche technology areas to maintain and develop the division’s technological capabilities as well as core competencies.
Jegadeesh has extensive experience in the Route Scouting, Process Development, DoE, QbD, Process Hazard Assessment, Development of Flow Processes, Salt and Polymorph Screening, Process Optimization, Technology Transfer and Scale up to support Preclinical to late phase development. Prior to joining Syngene, Jegadeesh worked for General Electric Co as a Research Scientist at the John F Welch Technology centre, Bangalore. Preceding that, he was a Post Doctoral Fellow at the Laboratoir de Genie Chimie, Institut National Polytechnique, Toulouse, France.
Jegadeesh obtained his PhD (Tech) in Chemical Technology from University Department of Chemical Technology, Mumbai and is a member of the Indian Institute of Chemical Engineers (MIIChE). He holds several patents in the Product and Process Development areas and has publications to his credit in peer-reviewed journals.
Ajit Simh Joined Syngene in April 2014 bringing 30 plus years of Corporate and Quality leadership to strengthen Syngene’s existing global regulatory compliance platform.
Ajit has been employed in the biotechnology / pharmaceutical industry in the US for 30 plus years after receiving his post-graduate degree in cell biology. His experience with both large and small to mid-size pharmaceutical companies at Mallinckrodt, Inc., Abbott Biotech, Baxter Healthcare and others includes R&D, production, operations and regulatory compliance. Over the years, Ajit has gained an excellent understanding on the global regulatory compliance requirements by the US FDA and ICH bodies for the manufacture and control of small and large molecule API’s and oral and parenteral dosage forms. He has worked with several companies in the US and internationally over the years to prepare them for US and EU inspection readiness. Ajit is active in academia and is an adjunct professor with a dual appointment at the University of California, San Diego and San Diego State University teaching classes in the M.S program in regulatory compliance and advanced quality.
The material and information contained on this Website is provided for general information purposes only and should not be relied on for making business decisions without consulting primary sources of information or specific professional advice. None of Website's content will be constitute any type of offer or contractual obligation by Biocon. Biocon reserves the right to revise, amend or modify this Website at any time and in any manner at its sole discretion.
This Web site is provided "as is" and Biocon does not, expressly or impliedly, warrant, guarantee or make any representations concerning the use, results of use or inability to use or access the information or contents of the Website, in terms of the accuracy, reliability, completeness, functionality, performance, continuity, timeliness or otherwise, fitness for a particular purpose and/or non-infringement.
Biocon assumes no responsibility for information contained in this Website and specifically disclaims any and all liability, whether based in contract, tort, strict liability or otherwise, for any direct, indirect, incidental, consequential, or special damages arising out of or in any way connected with access to or use of the Website, its content, or downloading any from it, errors, inaccuracies, mistakes, negligence, omissions, or misleading or defamatory statements, even if Biocon has been advised of the possibility of such damages, reliance on the content, delays in transmission, interruption in telecommunications, viruses, theft or destruction of information, acts of God, or unauthorized access to the Website or related information. Biocon specifically disclaims any and all liability arising from any content posted by a third party on any bulletin board contained in this Website, including any content which may be offensive, profane or obscene. Biocon reserves the right to remove content that is deemed unacceptable. The Web Site may contain links to other Web Sites operated by third parties. Biocon is not responsible for the privacy practices or policies of such third party Web Sites. The User will be solely responsible for privacy and secrecy of such information.
Biocon does not guarantee response to any e-mails received by Biocon through their Website. Biocon does not warrant the privacy and/or security of e-mails during internet transmission.
Biocon generates and maintains this Website from India and Indian Laws will have exclusive jurisdiction over this Website. The User hereby consents and submits to the exclusive jurisdiction of courts of Bangalore regarding any disputes arising out of or in connection with this Website.
All trademarks used and appearing on the Website, except those specifically excluded by reference, belong exclusively to Biocon. All rights, title and interests accruing from the same, statutory or otherwise wholly and absolutely vest with Biocon. Any use of Biocon's trademarks without prior written approval would constitute an offence under the laws of India and international treaties governing the same. Trade marks or brand names of third parties, if any, appearing on the Website, is duly acknowledged as belonging to the lawful owners of the said trademarks.
Except as otherwise noted on this Website, the contents of this Website are copyrighted © 2008 by Biocon. All rights are reserved. No part of the information on this Website, including text, graphics and html code, may be reproduced or transmitted in any form by any means without the express written consent of Biocon. The owners of copyrights are Biocon its affiliates or third party licensors. Biocon reserves the right to remove any content or links that allegedly infringes any other person's copyright at any point of time. Contents on the Website which belong to third party have been reproduced after taking prior permission from the said party and the copyright of such contents would remain exclusively with the said third party. Biocon shall not be responsible for any mistakes which might appear in such contents.